New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 17, 2014
11:07 EDTMYL, ACORAcorda sues Mylan over plans to duplicate Ampyra MS drug, Bloomberg says
News For ACOR;MYL From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 >>
August 26, 2015
06:55 EDTMYLMylan shares may sell off on affirmative Perrigo deal vote, says BMO Capital
With Mylan (MYL) set to hold a shareholder vote on August 28 regarding its proposed acquisition of Perrigo (PRGO), BMO Capital analyst David Maris predicts that if the vote goes in Mylan's favor, he expects Perrigo shares to rise and Mylan shares to fall. Afterward, he feels added overhangs, such as Teva's (TEVA) and Abbott's (ABT) shareholdings and potential short-term selling by arbitrageurs, will come into play, further pressuring Mylan shares.
05:58 EDTMYLPerrigo CEO says company is 'very active in M&A,' Bloomberg reports
Subscribe for More Information
August 25, 2015
16:43 EDTACOROn The Fly: Top stock stories for Tuesday
Subscribe for More Information
15:02 EDTMYLMylan says USPTO institutes IPR of two Copaxone patents
Subscribe for More Information
14:40 EDTMYLTeva Copaxone patents to be reconsidered by regulators, Bloomberg says
14:16 EDTMYLMylan launches generic version of Pfizer's Zosyn Injection
Mylan (MYL) announced the U.S. launch of Piperacillin and Tazobactam for Injection USP, 3.375g Single-dose Vials, which is the generic version of Pfizer's (PFE) Zosyn Injection. This product is a combination penicillin-class antibacterial and beta-lactamase inhibitor indicated for the treatment of patients with moderate to severe infections caused by susceptible isolates of certain bacteria. Piperacillin and Tazobactam for Injection USP, 3.375g Single-dose Vials had U.S. sales of approximately $72.1M for the 12 months ending June 30, 2015, according to IMS Health. Mylan's launch of this product adds to the company's growing portfolio of more than 145 injectable products available to patients in the U.S. across a broad array of therapeutic categories including oncology, anti-infectives, anesthesia/pain management and cardiovascular.
13:22 EDTMYLMylan comments on 'misleading' Perrigo statements
Subscribe for More Information
11:27 EDTMYLTeva to refrain from voting at Mylan special meeting
Subscribe for More Information
09:13 EDTACOROn The Fly: Pre-market Movers
Subscribe for More Information
09:03 EDTACORAcorda has major overhang removed by IPR denials, says Leerink
Subscribe for More Information
August 24, 2015
18:55 EDTACOROn The Fly: After Hours Movers
Subscribe for More Information
18:52 EDTACORJazz, Celgene, Shire up after USPTO rejects Acorda patent challenge
Subscribe for More Information
17:45 EDTACORAcorda Therapeutics up 31.2% after PTAB denies both IPRs of Ampyra patents
Subscribe for More Information
17:44 EDTACORAcorda Therapeutics announces PTAB denies both IPRs of Ampyra patents
Acorda Therapeutics announced that the United States Patent and Trademark Office, or USPTO, Patent Trials and Appeal Board. or PTAB, will not institute the inter partes review, or IPR, of U.S. Patent Nos. 8,663,685 and 8,007,826. The '685 and '826 patents are two of five Orange Book-listed patents that apply to Ampyra Extended Release Tablets, 10 mg, a novel treatment for multiple sclerosis developed by Acorda. Ampyra is a standard of care for improving walking in MS. The '685 and '826 patents are set to expire in 2025 and 2027, respectively.
August 21, 2015
15:22 EDTMYLMylan clarifies certain inaccuracies related to lowered condition to acquire Perrigo
Subscribe for More Information
08:19 EDTMYLMylan to host special shareholder meeting
Subscribe for More Information
August 18, 2015
11:34 EDTMYLMylan says FDA warning on Agila facilities has no material impact on forecast
Subscribe for More Information
10:19 EDTMYLMylan calls active on speculation of an activist investor stake
Mylan August 55 and 60 calls are active on total call volume of 7,900 contracts (800 puts) on speculation of an activist investor stake. August call option implied volatility is at 42, September is at 38; compared to its 52-week range of 22 to 52. Active call volume suggests traders taking positions for upside price movement.
10:01 EDTMYLRumor: Mylan moves higher on speculation of an activist investor stake
07:32 EDTMYLMylan sued in connection with filing of ANDA for Abiraterone Acetate Tablets
Subscribe for More Information
1 | 2 >>

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use